Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
World game at war: why some European nations have threatened a World Cup boycott 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
HENDERSON, Nev., May 01, 2018 -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion. Both the expanded animal testing and human trials are being conducted to support the company’s HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA.
“After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed,” said Douglas K. Beplate, CEO, UHP. “We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA.”
About Premarket Approval (PMA): https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketapprovalpma/
About United Health Products, Inc.
United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464
